Cervical cancer is one of the most common neoplastic diseases affecting women, with a worldwide incidence of almost half a million cases. A history of smoking and use of oral contraceptives have been confirmed to be risk factors for cervical cancer. Genetic susceptibility and immune response, especially impaired cellular immune response, may well be related to the development of cervical cancer. NBS1 is one of the key proteins participating in the recognition and repair of double-strand breaks that may lead to genomic instability and cancer if unrepaired. The objective of the present study was therefore to investigate NBS1 Glu185Gln gene polymorphisms and the risk of cervix cancer in a northern Indian population. We found that passive smokers having particular NBS1 genotypes (Glu/Gln, Gln/Gln or Glu/Gln + Gln/Gln) have an increased risk of developing cervix cancer (OR 5.21, p=0.000001; OR 4.60, p=0.001; OR 5.10, p=0.0000009, respectively). The risk was increased 2.4-fold in oral contraceptive users with a Glu/Gln genotype. We conclude that the risk of cervical cancer is increased in passive smokers and in users of oral contraceptives with certain NBS1 genotypes.
ParkinM.D., BrayF., FerlayJ., PisaniP.. Estimating the world cancer burden: Globocan 2000.Int J Cancer2001; 94: 153–6.
2.
ParkinD.M., PisaniP., FerlayJ.. Global cancer statistics.CA Cancer J Clin1999; 49: 33–64.
3.
MooreM.A., TajimaK.. Cervical cancer in the Asian pacific-epidemiology, screening and treatment.Asian Pac J Cancer Prev2004; 5: 349–61.
4.
SchoellW.M.J., JaniceK.M.F., MirhashemiR.. Epidemiology and biology of cervical cancer.Sem Surg Oncol1999; 16: 203–11.
5.
Settheetham-IshidaW., SingtoY., YuenyaoP., TassaneeyakulW., KanjanavirojkulN., IshidaT.. Contribution of epigenetic risk factors but not p53 codon 72 polymorphism to the development of cervical cancer in northeastern Thailand.Cancer Lett2004; 210: 205–11.
6.
SobtiR.C., KaurS., KaurP., SinghJ., GuptaI., JainV., NakaharaA.. Interaction of passive smoking with GST (GSTM1, GSTT1, and GSTP1) genotypes in the risk of cervical cancer in India.Cancer Genet Cytogenet2006; 166: 117–23.
7.
CokerA.L., BondS.M., WilliamS.A., GerasimovaT., PirisiL.. Active and passive smoking, high risk human papillomavirus and cervical neoplasia.Cancer Detect Prev2002; 26: 121–8.
8.
TayS.K., TayK.J.. Passive cigarette smoking is a risk factor in cervical neoplasia.Gynecol Oncol2004; 93: 116–20.
9.
BertramC.C.. Evidence for practice: oral contraception and risk of cervical cancer.J Am Acad Nurse Pract2004; 16: 455–61.
10.
MatosA., MoutinhoJ., PintoD., MedeirosR.. The influence of smoking and other cofactors on the time to onset to cervical cancer in a southern European population.Eur J Cancer Prev2005; 14: 485–91.
11.
CastellsaguéX., MuñozN.. Cofactors in human papillomavirus carcinogenesis—role of parity, oral contraceptives, and tobacco smoking.J Natl Cancer Inst Monogr2003; 31: 20–8.
12.
FrazerI.H.. Immunology of papillomavirus infection.Curr Opin Immunol1996; 8: 484–91.
13.
RohJ., KimM., KimJ.. Polymorphism in codon 31 of p21 and cervical cancer susceptibility in Korean women.Cancer Lett2001; 165: 59–62.
14.
HajeerA.H., HutchinsonI.V.. Influence of TNF-a gene polymorphisms on TNF-a production and disease.Hum Immunol2001; 62: 1191–9.
15.
GhaderiM., Nikitina ZakeL., WallinK.. Tumor necrosis factor A and MHC class I chain related gene A (MIC-A) polymorphisms in Swedish patients with cervical cancer.Hum Immunol2001; 62: 1153–6.
16.
NanavatyU., GoldsteinA.D., LevinS.J.. Polymorphisms in candidate asthma genes.Am J Med Sci2001; 321: 11–6.
17.
LaiH.C., SytwuH.K., SuncA., YuM.H., YuC.P., LiuH.S.. Single nucleotide polymorphism at Fas promoter is associated with cervical cancer.Int J Cancer2003; 103: 221–5.
18.
WoodR.D., MitchellM., SgourosJ., LindahlT.. Human DNA repair genes.Science2001; 291: 1284–9.
19.
FordB.N., RuttanC.C., KyleV.L., BrackleyM.E., GlickmanB.W.. Identification of single nucleotide polymorphisms in human DNA repair genes.Carcinogenesis2000; 21: 1977–81.
20.
MohrenweiserH.W., WilsonDM3rd, JonesI.M.. Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes.Mutat Res2003; 526: 93–125.
21.
LuJ., WeiQ., BondyM.L.. Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women ≤55 years.Carcinogenesis2006; 27: 2209–16.
22.
KobayashiJ., AntocciaA., TauchiH., MatsuuraS., KomatsuK.. NBS1 and its functional role in the DNA damage response.DNA Repair (Amst)2004; 3: 855–61.
23.
MedinaP.P., AhrendtS.A., PollanM., FernandezP., SidranskyD., Sanchez-CespedesM.. Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1–185Gln variant and p53 gene mutations.Cancer Epidemiol Biomarkers Prev2003; 12: 699–704.
24.
HebbringS.J., FrederikssonH., WhiteK.A.. Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer.Cancer Epidemiol Biomarkers Prev2006; 15: 935–8.
25.
VaronR., ReisA., HenzeG.. Mutations in the NBS1 gene in childhood acute lymphoblastic leukemia (ALL).Cancer Res2001; 61: 3570–2.
26.
RoeB.A., CrabtreeJ.S., KhanA.S.. DNA isolation and sequencing.Essential technique series.New York: John Wiley and Sons, 1996.
27.
ShenM., LanQ., ZhangL.. Polymorphisms in genes involved in DNA double strand break repair pathway and susceptibility to benzene induced hepatotoxicityCarcinogenis2006; 27: 2083–9.
28.
StrackerT.H., CarsonC.T., WeitzmanM.D.. Adenovirus oncoproteins inactivate the Mre 11-Rad50-NBS1 DNA repair complex.Nature2002; 418: 348–52.
29.
HainautP., HousteinM.. P53 and human cancer: the first ten thousand mutations.Adv Cancer Res2000; 77: 81–137.
30.
David-BeabesG.L., LunnR.M., LondonS.J.. No association between the XPD (Lys751Gln) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk.Cancer Epidemiol Biomarkers Prev2001; 10: 911–12.
31.
KuschelB., AuranenA., McBrideS.. Variants in DNA double-strand break repair genes and breast cancer susceptibility.Hum Mol Genet2002; 11: 1399–407.
32.
PopandaO., TanX.L., AmbrosoneC.B.. Genetic polymorphisms in DNA double-strand break repair genes XR-CC3, XRCC2, and NBS1 are not associated with acute side effects of radiotherapy in breast cancer patients.Cancer Epidemiol Biomarkers Prev2006; 15: 1048–50.
33.
ForstiA., AngeliniS., FestaF.. Single nucleotide polymorphism in breast cancer.Oncol Rep2004; 11: 917–22.
34.
LanQ., ShenM., BerndtS.I.. Smoky coal exposure, NBS1 polymorphisms, p53 protein accumulation, and lung cancer risk in Xuan Wei, China.Lung Cancer2005; 49: 317–23.
35.
RykC., KumarR., ThirumaranR.K., HouS.M.. Polymorphisms in the DNA repair genes XRCCI, APEXI, XRCC3 and NBS1, and the risk for lung cancer in never and ever smokers.Lung Cancer2006; 54: 285–92.
36.
SomaliS., FabiolaF., ShiferuS.. Polymorphism in DNA repair and metabolic genes in bladder cancer.Carcinogenesis2004; 25: 729–34.
37.
RykC., KumarR., SanyalS.. Influence of polymorphism in DNA repair and defense genes on p53 mutation in bladder tumours.Cancer Lett2005; 241: 142–9.
38.
MatulloG., DunningA.M., GuarreraS.. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study.Carcinogenesis2006; 27: 997–1007.
39.
VaronR., SchochC., ReisA., HiddemannW.C., SperlingK., SchnittgerS.. Mutation analysis of the NBSI gene in nineteen patients with acute myeloid leukemia with complex karyotype.Leuk Lymphoma2003; 44: 1931–4.
40.
CerosalettiK.M., MorrisonV.A., SabathD.E., WillerfordD.M., ConcannonP.. Mutations and molecular variants of the NBS1 gene in non-Hodgkin lymphoma.Gene Chromosomes Cancer2002; 35: 282–6.
41.
Plisiecka-HalasaJ., Dansonka-MieszkowskaA., RembiszewskaA., BidzinskiM., SteffenJ., KupryjanczykJ.. Nijmegen breakage syndrome gene 1 (NBS1) alternations and its protein (nibrin) expression in human ovarian tumours.Ann Hum Genet2002; 66: 353–9.
